To compare resource use during the last 6 months of life of individuals diagnosed with Alzheimer's disease (AD) but for whom AD was not formally identified as the underlying cause of death (dying with AD) with that of those who had AD as underlying cause of death (dying of AD). DESIGN: Full-population retrospective analysis. SETTING: Belgium. PARTICIPANTS: All Belgian decedents in 2012. MEASUREMENTS: We linked participants' healthcare, population, and death certificate data. Those who died of AD were selected based on underlying cause of death. Those who died with AD were selected using a validated algorithm. RESULTS: Individuals who died of AD had less hospital use than those who died with AD; were less often admitted to a palliative care unit but received palliative home care services slightly more often; and had use of physiotherapy, noninvasive ventilation, medical imaging, sedatives, oxygen, and opioids comparable with that of those who died with AD. CONCLUSION: During the last 6 months of life, individuals dying of AD used fewer intensive resources such as intensive care unit, cardiopulmonary resuscitation, and invasive ventilation than those dying with AD, which suggests the effect of recognition of an end-of-life phase. Overall, individuals with AD rarely used palliative care services, suggesting a need for more efforts to encourage use of palliative care in individuals with AD. J Am Geriatr Soc 66: 879-885, 2018. Key words: Alzheimer's disease; end-of-life; resource use; administrative database; full population; retrospective D uring the past century, improvements in health care have contributed to people living longer and healthier lives, which has resulted in an increase in the number of people with noncommunicable diseases such as dementia. In 2015, 46.8 million people worldwide were living with dementia, and their number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.
D
uring the past century, improvements in health care have contributed to people living longer and healthier lives, which has resulted in an increase in the number of people with noncommunicable diseases such as dementia. In 2015, 46.8 million people worldwide were living with dementia, and their number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050. 1 Dementia is a general term comprising different types of mental decline. The most common type of dementia is Alzheimer's disease (AD), which accounts for an estimated 60% to 80% of cases. 2 The end stage of AD lasts an average of 2 years, 3 and individuals may develop apraxia and dysphagia and, at a later stage, often have reduced mobility, which increase the risk of infection. 4 These infections, such as pneumonia, might increase mortality in individuals with AD and are often seen as an underlying cause of death. As a result, dementia is often seen as a predisposing or contributing factor to the terminal infection rather than the cause of death. 5 Moreover, prognostic markers to identify the last 6 months of life in AD (e.g., functional dependency, recurrent hospitalizations, and weight loss) cannot predict the end of life. 6 Given the lack of formal recognition of AD as a life-threatening disease and of reliable prognostic markers and variability of survival in individuals with AD, clinicians do not see AD as a primary cause of death or a disease from which one dies. 6 Not recognizing dementia as a possible cause of death might result in a limited chance to obtain support or access customized treatment, formal end-of-life care, and healthcare services or might result in receiving care and services on a general basic level not adjusted to their end-of-life needs. 7, 8 Recognition of dementia as a possible cause of death could have important implications in terms of resource use at the end of life, including palliative care.
It can be hypothesized that, of individuals with AD, those diagnosed with AD but for whom AD was not formally identified as the underlying cause of death on the death certificate would have a different resource use pattern during the final months of life than those who died of AD and had AD indicated as the underlying cause of death.
To fill this gap in knowledge about management of individuals with dementia at the end of life, the aim of this study was to describe, at a population level, medical resource use in the final months of life in people with AD and to compare the resource use of those diagnosed with AD but for whom AD was not formally identified as the underlying cause of death on the death certificate (dying with AD) with that of those who had AD indicated as the underlying cause of death (dying of AD).
MATERIALS AND METHODS
The present study was a retrospective full population analysis of Belgians who died with or of AD during 2012.
Data sources
Eight population-level databases were linked into one common database. Data included healthcare data retrieved from the Intermutualistic Agency (IMA); sociodemographic, socioeconomic, and death certificate data retrieved from Statistics Belgium; and cancer diagnosis data retrieved from the Belgian Cancer Registry. A more detailed description of these databases and the procedures for obtaining and linking these data is presented elsewhere. 9 The IMA databases include all reimbursement data for healthcare consumption and pharmaceutical prescriptions from all Belgian health insurance organizations. Because health insurance is mandatory in Belgium, reimbursement data for all legal residents are available. Moreover, thorough quality procedures result in good reliability of the database for healthcare research. 10 The Statistics Belgium databases include sociodemographic data from the population registry, 11 socioeconomic data from the Socioeconomic Survey 2001 and Census 2011, and death certificate data for all deaths. 12 
Study population
The study population consisted of all persons who died with AD in Belgium during 2012. We compared end-oflife resource use of individuals diagnosed with AD but for whom AD was not formally identified as the underlying cause of death on the death certificate (dying with AD) and those who had AD (International Classification of Diseases, 10th Revision, codes F00 and G30) indicated as the underlying cause of death on the death certificate (dying of AD). Diagnosis of AD was identified algorithmically using medication data from 2002 through 2012. This validated algorithm was based on existing evidence and discussed with experts in AD treatment and administrative healthcare databases (Appendix S1). The final algorithm was further expanded with deaths for which AD was recorded on the death certificates as an intermediate or associated cause of death but excluding deaths for which AD was the underlying cause of death.
Measures
The primary study outcome was resource use in the last 6 months of life of individuals with AD, differentiating whether individuals with AD had AD indicated as an underlying cause of death on their death certificate or not.
All healthcare (coded as nomenclature codes) and medication (coded as Anatomical Therapeutic Chemical Classification (ATC) codes) data were interpreted and aggregated into meaningful resource use, procedure, and medication categories.
Participant characteristics included age at death, sex, urbanization level of the municipality of residence, highest obtained educational level, household type, housing comfort, and net taxable income.
Periods of 180, 90, and 30 days before death were defined for analysis purpose based upon the dates related to the specific nomenclature numbers or medication prescription dates.
Statistical Analysis
To investigate potential differences, we compared characteristics and resource use of individuals dying of AD with those of individuals dying with AD using chi-square tests for categorical variables and Wilcoxon rank-sum tests for continuous variables and calculated relative risks of having each type of resource use for those who died with AD and those who died of AD during 180-, 90-, and 30-day periods before death. We also analyzed resource data using a general linear model for continuous variables and logistic regression for binary variables, with dying of versus with AD as a dependent variable and controlling simultaneously for various covariates (age, sex, household type, housing comfort, attained educational level, urbanization level of municipality of residence, net taxable income, having a cancer diagnosis, Charlson Comorbidity Index, level of care need, place of death). We set the significance level at p .05 to address hypothesis testing and performed all analyses using SAS version 7.13 HF1 (7.100.3.5419) (64-bit) (SAS Institute, Inc., Cary, NC).
RESULTS
In 2012, 109,034 people died in Belgium, of whom 107,847 (98.9%) were insured with 1 of the 7 sickness funds and hence had data about reimbursed health care and medication; for 1,187 deaths, mainly those working for the European government (covered by an insurance scheme of the European Union), homeless persons, and those with unauthorized immigration, such data were not available.
Eleven thousand four hundred ten persons (10.6% of all deaths) died with or of AD. Of these, 8,804 (77.2%) died with AD, and 2,606 (22.8%) died of AD, the average age was 85 6 6.6, and the majority were female, married, and lived in an urban region (Table 1) . Although those who died with AD had a higher comorbidity index than those who died of AD, the groups differed only marginally in terms of age, sex, educational level, household, and housing comfort and had a comparable mean net taxable income.
For almost all types of resource use and procedures, use during the final 6 months of life in those who died with AD tended to be similar to or higher than that of those who died of AD (Table 2 ). Those dying with AD had a higher probability of having at least 1 hospital admission (61.1% vs 40.5%, p<.001), were more likely to have had an intensive care unit (ICU) stay (8.7% vs 2.0%, p<.001) and home care service use (32.4% vs 25.4%, p<.001), and were more often admitted to a palliative care unit (2.2% vs 1.2%, p5.002). Both, those dying with and of AD had a mean number of 12 contacts with a general practitioner during the last 6 months of life. Finally, a greater proportion of those dying with AD (40.8%) had at least one specialist contact during the last 6 months of life than of those who died of AD (27.9%) (p<.001). Those dying with AD were slightly less likely to receive palliative home care services (5.5% vs 6.8%, p5.01) and had fewer palliative home care days during the last 6 months of life (63.2 vs 83.5 days). Those dying with AD were slightly less likely to stay in a nursing home (70.1%) than those who died of AD (80.0%) (p<.001). In both groups, all resources increased when approaching death (Supplementary Figure S1a, b) , but home care use and specialist contacts decreased.
In terms of procedures undergone during the last 6 months of life, those who died with AD were more likely to undergo invasive ventilation (p<.001) and to be resuscitated (p<.001) and had higher use of medical imaging (p<.001) than those who died of AD (Table 3) . Those dying with AD were slightly more likely to use opioids (p5.05), morphine (p<.001), and sedatives (p<.001) than those who died of AD. The use of these medications increased substantially during the final 6 months of life in both groups (Supplementary Figure S2) . Those dying of AD were less likely to use dementia medication than those dying with AD (p<.001); their use remained stable during the last 6 months of life in those who died with AD but decreased in those who died of AD.
DISCUSSION
Our observational study of all individuals who died from AD is the first, to our knowledge, to describe resource use on a full population level during the last 6 months of life, comparing individuals diagnosed with AD but for whom AD was not formally identified as the underlying cause of death on the death certificate (dying with AD) and those who had AD indicated as the underlying cause of death on the death certificate (dying of AD). Our results indicate that palliative care services available at home or a palliative care unit are not always considered in the care plans of individuals with AD, and hospitalization, intensive care, and emergency department admissions near the end of life are common in those who die with or of AD. Those who died with AD had a resource use during the last 6 months of life that was similar to or greater than that of those who died of AD, but they were less likely to receive palliative home care services and slightly more likely to be admitted to a palliative care unit.
The high use of intensive resources at the end of life of those with AD may be a result of the disease course of AD. In contrast to many other diseases with a predictable prognosis, such as cancer, that reach an advanced stage followed by a predictable downhill course over weeks or months, prognostication with AD is more difficult. This corroborates previous findings that the end-of-life phase in noncommunicable diseases, specifically AD, is often not recognized or is neglected because of the absence of prognostic markers or difficulties in diagnosing. 13 Our results indicate that individuals with AD at the end of life have frequent contacts with their general practitioners, which creates an opportunity for recognizing end-stage AD and discussing end-of-life approaches. Previous research shows that general practitioners encounter several difficulties when discussing end-of-life care in individuals with AD, 14, 15 although recognition of an end-of-life phase and timely initiation of palliative care may improve end-of-life care and, moreover, quality of life of individuals with AD.
Our study also revealed important differences between individuals dying of AD and those dying with AD. Those who died with AD had more intensive resource use than those who died of AD, although the differences in resource use could be related to the fact that the groups differ in terms of disease severity or number of comorbidities. Based on the Charlson Comorbidity Index, we found that those who died with AD had more severe comorbidities than those who died of AD, which indicates that those who died with AD were more likely to receive resources related to these coexisting diseases. Moreover, those who died with AD were more likely to die in a hospital than those who died of AD, indicating that those who died with AD received treatments or care adjusted to these specific coexisting diseases. Nevertheless, the differences found suggest the importance of adequate recognition of the end-of-life phase in individuals with AD. Despite indications of better recognition of the dying phase in those dying of AD, the absolute percentage of individuals dying of AD using palliative care services is still rather low and may point to a need for better (and earlier) identification of individuals who can benefit from palliative care and greater awareness of the benefits of palliative care in AD. In addition to recognition of the dying phase, identification of those who could benefit from palliative care provision would thus also be needed to improve end-of-life care in AD. A systematic review concluded that validated prognostic models to predict for whom palliative care would be beneficial are lacking for routine clinical use in individuals with dementia, 16 although another study found that the use of the Mini-Suffering State Examination can help to identify those who could benefit from palliative care provision. 17 Several possible limitations of our study must be acknowledged. A number of confounders (e.g., disease severity, specific comorbidities, place of death or care) that could influence the recognition of the end-of-life period might influence decisions regarding end-of-life care plans in individuals with AD, but because we used administrative databases and lacked specific diagnostic information, we could not account for specific confounders such as number and characteristics of palliative care practitioners or number of specific comorbidities. Nevertheless, based on a specific algorithm using intermediate and associated causes of death mentioned on the death certificate, we were able to measure the Charlson Comorbidity Index. After controlling simultaneously for a number of possible confounders, we found that the differences in resource use between those who had AD as an underlying cause of death and those who did not was maintained (Supplemental file).
The use of death certificate data to identify individuals who died of and with AD has certain limitations. First, clinicians might often recognize AD as a contributor to death but might not prioritize the diagnosis in individuals with different comorbidities. Therefore, in individuals with different comorbidities, different doctors might choose different diagnoses to report as cause of death. Another wellknown weakness in using death certificates concerns the underreporting of AD on death certificates as a main and contributory cause of death, 18, 19 although our additional use of a validated medication-based algorithm partly mitigated that limitation in identifying those with AD. The combination of death certificate and medication data resulted in a more accurate number of those dying with AD. 20 The adequacy of the use of an algorithm based on pharmacy data, using claims data and pharmacy data from more than 3 years, to accurately identify those dying with AD has been confirmed in previous research, 21, 22 but because there is no criterion standard to use to identify those dying with AD, 23 the choice of grouping may have affected our results, resulting in a more heterogeneous group with more differing morbidities for which they were treated. Despite these limitations, our study has a number of exceptional strengths. The use of a full population-linked administrative and healthcare database resulted in a large sample size and has good statistical power, which made the study of resource use in individuals with AD at the end of life possible. Moreover, the completeness of the unique linked database ensures representativeness in a real-world setting. Furthermore, the completeness and independent data collection minimize the effect of selection bias due to nonresponse and loss to follow-up (attrition) or influences of the diagnostic process determined by the study. 24 
CONCLUSION
Based on a retrospective analysis using a full populationlinked database, individuals who died of AD used fewer resources than those who died with AD, suggesting that recognition of end-stage AD as an end-of-life condition may influence the use of less intensive resources such as palliative care services and hence appropriateness of endof-life care. In addition to the importance of and difficulties in recognizing end-stage AD, we found that the level of home palliative care for individuals dying of AD was low, indicating a need for more efforts to encourage its timely use in individuals with AD. Moreover, recognizing AD as a disease from which one could die and the related recognition of the end-stage phase are important factors to provide end-of-life care adapted to the specific needs of individuals with AD.
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